Study of CM310 Injection in Subjects With Moderate-to-Severe Atopic Dermatitis
NCT ID: NCT05715320
Last Updated: 2024-10-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
160 participants
INTERVENTIONAL
2023-03-10
2024-07-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Subcutaneously CM310/Placebo in Patients With Moderate-to-Severe Atopic Dermatitis (AD)
NCT04805411
A Study of CM310 in Subjects With Moderate-to-Severe Atopic Dermatitis
NCT06116565
A Study of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis
NCT05265923
The Study of CM310 in Patients With Atopic Dermatitis
NCT04893707
A Study of CM310 in Children Patients With Moderate-to-severe Atopic Dermatis
NCT05579925
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A
CM310, subcutaneous
CM310
IL-4Rα monoclonal antibody
Group B
CM310, subcutaneous
CM310
IL-4Rα monoclonal antibody
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CM310
IL-4Rα monoclonal antibody
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age ≥ 18 and ≤ 75 years old, male or female.
* The fertile subjects agreed to take effective contraceptive measures throughout the study period.
* The subjects can communicate well with the investigators and complete the follow-up according to the protocol.
Exclusion Criteria
* He received allergen-specific immunotherapy (desensitization therapy) within 6 months before randomization.
* Major surgery is planned during the study period.
* Previous history of atopic keratoconjunctivitis and corneal involvement.
* Other combined skin diseases that may affect the evaluation of the study.
* Confronting IL-4R α Monoclonal antibody or CM310/placebo drug or ingredient allergy.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Keymed Biosciences Co.Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hangzhou First People's Hospital
Hangzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CM310-101109
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.